Grading allergic ocular disease

Article

Research published online ahead of print by Graefe's Archive for Clinical and Experimental Ophthalmology, has revealed that allergic ocular diseases can be classified and clinically evaluated using a grading system.

Research published online ahead of print by Graefe's Archive for Clinical and Experimental Ophthalmology, has revealed that allergic ocular diseases can be classified and clinically evaluated using a grading system.

Eiichi Uchio and colleagues from Fukuoka University School of Medicine, Japan created a number of criteria for classifying and clinically evaluating the severity of allergic ocular diseases. They then evaluated the effectiveness of the criteria in the diagnosis of 1,079 patients.

The researchers diagnosed and classified allergic conjunctivitis, atopic keratoconjunctivitis and vernal keratoconjunctivitis based on local and systemic clinical findings. Ten objective conjunctival, limbal and corneal lesion findings were graded on a four-point scale. The total score was used as the clinical score, with a highest value of 30.

Of the 1,079 subjects, 876 (81.2%) were diagnosed with seasonal allergic conjunctivitis, 115 (10.7%) with perennial allergic conjunctivitis, 47 (4.4%) with atopic keratoconjunctivitis and 41 (3.8%) with vernal keratoconjunctivitis. The total clinical scores were 1.54 in seasonal allergic conjunctivitis, 2.13 in perennial allergic conjunctivitis, 3.72 in atopic keratoconjunctivitis and 12.68 in vernal keratoconjunctivitis.

The authors concluded that re-evaluation of allergic ocular disease is necessary for building future strategies for its treatment.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.